Stellaromics Valuation, Funding & Investors
Stellaromics is valued at $163M as of February 2025.
Last Stellaromics valuation
$163M
Series B · Feb 2025
Last Stellaromics funding round
$80M
Series B · Feb 2025
Cumulative funding Stellaromics raised
$105M
across 2 funding rounds
Key investors in Stellaromics
Stanford University
Plaisance Capital Management
Catalyst4
About Stellaromics
Stellaromics is a South San Francisco-based biotechnology firm pioneering 3D in situ multi-omics sequencing. The platform maps spatial transcriptomics, proteomics, and genomics in tissues at single-cell resolution, aiding drug discovery for oncology and immunology researchers.
Founded
2022
HQ
Boston, MAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$163M (Feb 2025)
Stellaromics Valuation
Stellaromics is currently valued at $163M, based on its Series B in February 2025.
The $80M round was led by Catalyst4, with participation from Stanford University.
Stellaromics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Feb 2025 | Series B | $163M |
Stellaromics Funding History
Stellaromics has raised a total of $105M across 2 funding rounds.
Stellaromics' first fundraising round was a $25M Series A in November 2023. The most recent completed round was a $80M Series B in February 2025.
Stellaromics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Feb 2025 | Series B | Catalyst4 (lead); Stanford University | $80M | $163M | Stellaromics is a startup developing multiomics technology for spatial biology, enabling researchers to analyze the spatial organization of cells and tissues in 3D. Its flagship product, Pyxa, is an instrument that uses 3D sequencing to detect gene expression patterns, visualize cell clusters in intact tissue up to 100 µm thick or more, and provide genomics data. Founded in 2022 based on technology from Stanford bioengineer Karl Deisseroth and Broad Institute chemist Xiao Wang, the company is led by CEO Todd Dickinson, a former Illumina executive. In February 2025, Stellaromics completed an $80 million Series B funding round led by Catalyst4, a Silicon Valley nonprofit founded by Google cofounder Sergey Brin, with participation from Stanford University’s venture arm. This brought total capital raised to $105 million, following a $25 million Series A in 2023 from Plaisance Capital Management and a Silicon Valley family office. The Series B supports the commercial launch of Pyxa in the second half of 2025. Early users include researchers at Stanford, University of Glasgow, Scripps Research, and Oregon Health & Science University for neuroscience and cancer studies. As of February 11, 2025, Stellaromics was valued at $163 million post-round, with a capital efficiency ratio of 1.55x (valuation over total funding raised). The company operates in the spatial biology sector, competing among top players recognized in 2025 industry lists. |
| Nov 2023 | Series A | Plaisance Capital Management (lead) | $25M | - | - |
Who has invested in Stellaromics?
3 investors have backed Stellaromics across its funding rounds, including Stanford University, Plaisance Capital Management and Catalyst4.
Lead investors include Catalyst4 and Plaisance Capital Management.
Stellaromics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Francisco, CA | 1 | Participant | Feb 2025 | |
This data is available for Pro users. Sign up to see all 3 Stellaromics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialStellaromics Competitors
Stellaromics competitors include listed companies like Korro Bio and Cibus, and private ones like 54gene, Echosens, Mirvie and Global Fertility.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| United States | Private | - | - | $162M | - | |
 Paris | Private | - | - | $161M | - | |
| San Francisco, CA | Private | - | - | $155M | - | |
| United States | Publicly listed | $6M | ($112M) | $174M | 48.9x | |
 Dubai | Private | - | - | $175M | - | |
| United States | Publicly listed | $4M | ($91M) | $125M | 28.9x |
Stellaromics Public Comps
Stellaromics is still privately-owned, but its public comps include Korro Bio, Cibus, Veraxa Biotech, ToolGen, electroCore, Anixa Biosciences, Applied BioCode, Atrys Health, 3D Medicines and Osang Healthcare.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $6M | ($112M) | 15.8x | 48.9x | (0.9x) | (1.1x) | |||
| $4M | ($91M) | 37.8x | 28.9x | (1.5x) | (2.3x) | |||
| $29K | ($79M) | 7313.2x | - | (2.6x) | - | |||
| $951K | ($26M) | 211.6x | - | (7.8x) | - | |||
| $32M | ($12M) | 3.2x | 2.6x | (8.5x) | (16.5x) | |||
| - | ($12M) | - | - | (6.9x) | - | |||
| $15M | ($5M) | 5.0x | - | (14.2x) | - | |||
| $162M | ($12M) | 2.3x | 2.1x | (30.2x) | 14.9x | |||
This data is available for Pro users. Sign up to see all Stellaromics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Stellaromics
| When was Stellaromics founded? | Stellaromics was founded in 2022. |
| Where is Stellaromics headquartered? | Stellaromics is headquartered in Boston, MA, United States. |
| Is Stellaromics publicly listed? | No, Stellaromics is a private, VC-backed company. |
| What is Stellaromics' valuation? | Stellaromics was last valued at $163M in its Series B in February 2025. |
| How much funding has Stellaromics raised? | Stellaromics has raised $105M across 2 funding rounds. |
| What was Stellaromics' last funding round? | Stellaromics' last funding round was a $80M Series B in February 2025, led by Catalyst4. |
| Who are Stellaromics' investors? | Stellaromics' investors include Stanford University, Catalyst4 and Plaisance Capital Management. |
| Which companies are comparable to Stellaromics? | Companies comparable to Stellaromics include 54gene, Echosens, Mirvie, Korro Bio, Global Fertility and Cibus. |
See companies similar to Stellaromics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.